Research programme: non-opioid analgesics - Kineta

Drug Profile

Research programme: non-opioid analgesics - Kineta

Alternative Names: alpha9/alpha10 nicotinic acetylcholine receptor antagonists - Kineta; Conopeptide; CSP 4; CSP conopeptide; KCP 400; nAChR antagonists - Kineta

Latest Information Update: 19 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Utah
  • Developer Kineta; KPI Therapeutics
  • Class Conotoxins; Non-opioid analgesics; Peptides
  • Mechanism of Action Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 16 Apr 2018 Non-opioid analgesics licensed to Genentech for the treatment of chronic Pain
  • 22 Feb 2017 Kineta plans a phase I trial for Pain
  • 26 Jul 2016 KPI Therapeutics plans to file an IND in first half of 2017 (KPI Therapeutics website; July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top